These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31056744)

  • 1. Epidermal autophagy and beclin 1 regulator 1 and loricrin: a paradigm shift in the prognostication and stratification of the American Joint Committee on Cancer stage I melanomas.
    Ellis R; Tang D; Nasr B; Greenwood A; McConnell A; Anagnostou ME; Elias M; Verykiou S; Bajwa D; Ewen T; Reynolds NJ; Barrett P; Carling E; Watson G; Armstrong J; Allen AJ; Horswell S; Labus M; Lovat PE
    Br J Dermatol; 2020 Jan; 182(1):156-165. PubMed ID: 31056744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of epidermal AMBRA1 and loricrin (AMBLor) as a prognostic biomarker for nonulcerated American Joint Committee on Cancer stage I/II cutaneous melanoma.
    Ewen T; Husain A; Stefanos N; Barrett P; Jones C; Ness T; Long A; Horswell S; Bosomworth H; Lowenstein J; Richardson G; Swan D; McConnell A; Rose A; Andrew T; Reynolds N; Malvehy J; Carrera C; Alos L; Mailer S; Helm T; Ding L; Bogner P; Podlipnik S; Puig S; McArthur GA; Paragh G; Labus M; Sloan P; Armstrong JL; Lovat PE
    Br J Dermatol; 2024 Mar; 190(4):549-558. PubMed ID: 38006317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanoma secretion of transforming growth factor-β2 leads to loss of epidermal AMBRA1 threatening epidermal integrity and facilitating tumour ulceration.
    Cosgarea I; McConnell AT; Ewen T; Tang D; Hill DS; Anagnostou M; Elias M; Ellis RA; Murray A; Spender LC; Giglio P; Gagliardi M; Greenwood A; Piacentini M; Inman GJ; Fimia GM; Corazzari M; Armstrong JL; Lovat PE
    Br J Dermatol; 2022 Apr; 186(4):694-704. PubMed ID: 34773645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Impact of Autophagy Biomarkers for Cutaneous Melanoma.
    Tang DY; Ellis RA; Lovat PE
    Front Oncol; 2016; 6():236. PubMed ID: 27882308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromogenic in situ hybridization analysis of melastatin mRNA expression in melanomas from American Joint Committee on Cancer stage I and II patients with recurrent melanoma.
    Hammock L; Cohen C; Carlson G; Murray D; Ross JS; Sheehan C; Nazir TM; Carlson JA
    J Cutan Pathol; 2006 Sep; 33(9):599-607. PubMed ID: 16965333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Melanoma Nodal Positivity and Biopsy Rates Before and After Implementation of the 7th Edition of the AJCC Cancer Staging Manual.
    Isom C; Wheless L; Hooks MA; Kauffmann RM
    JAMA Dermatol; 2019 May; 155(5):572-577. PubMed ID: 30840034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combined immunohistochemical expression of AMBRA1 and SQSTM1 identifies patients with poorly differentiated cutaneous squamous cell carcinoma at risk of metastasis: A proof of concept study.
    Alexander MH; Cousins WJ; Ewen T; South AP; Lovat P; Stefanos N
    J Cutan Pathol; 2024 Jun; 51(6):450-458. PubMed ID: 38421158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease.
    Moncrieff MD; Lo SN; Scolyer RA; Heaton MJ; Nobes JP; Snelling AP; Carr MJ; Nessim C; Wade R; Peach AH; Kisyova R; Mason J; Wilson ED; Nolan G; Pritchard Jones R; Johansson I; Olofsson Bagge R; Wright LJ; Patel NG; Sondak VK; Thompson JF; Zager JS
    J Clin Oncol; 2022 Dec; 40(34):3940-3951. PubMed ID: 35849790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification.
    Ferris LK; Farberg AS; Middlebrook B; Johnson CE; Lassen N; Oelschlager KM; Maetzold DJ; Cook RW; Rigel DS; Gerami P
    J Am Acad Dermatol; 2017 May; 76(5):818-825.e3. PubMed ID: 28110997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of high-risk patients with a seven-biomarker prognostic signature for adjuvant treatment trial recruitment in American Joint Committee on Cancer v8 stage I-IIA cutaneous melanoma.
    Meyer S; Buser L; Haferkamp S; Berneburg M; Maisch T; Klinkhammer-Schalke M; Pauer A; Vogt T; Garbe C
    Eur J Cancer; 2023 Mar; 182():77-86. PubMed ID: 36753835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AMBRA1 has an impact on melanoma development beyond autophagy.
    Di Leo L; De Zio D
    Autophagy; 2021 Jul; 17(7):1802-1803. PubMed ID: 34156327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic significance and impact of the CXCR4-CXCR7-CXCL12 axis in primary cutaneous melanoma.
    McConnell AT; Ellis R; Pathy B; Plummer R; Lovat PE; O'Boyle G
    Br J Dermatol; 2016 Dec; 175(6):1210-1220. PubMed ID: 27167239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of the AJCC 7th edition change in T1 melanoma substaging on national utilization and outcomes of sentinel lymph node biopsy for thin melanoma.
    Hieken TJ; Grotz TE; Comfere NI; Inselman JW; Habermann EB
    Melanoma Res; 2015 Apr; 25(2):157-63. PubMed ID: 25647736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV.
    Owen SA; Sanders LL; Edwards LJ; Seigler HF; Tyler DS; Grichnik JM
    Cancer; 2001 Mar; 91(5):983-91. PubMed ID: 11251950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors.
    Waninger JJ; Ma VT; Journey S; Skvarce J; Chopra Z; Tezel A; Bryant AK; Mayo C; Sun Y; Sankar K; Ramnath N; Lao C; Sussman JB; Fecher L; Alva A; Green MD
    JAMA Netw Open; 2021 Mar; 4(3):e210980. PubMed ID: 33687443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. American Joint Committee on Cancer clinical stage as a selection criterion for sentinel lymph node biopsy in thin melanoma.
    Vaquerano J; Kraybill WG; Driscoll DL; Cheney R; Kane JM
    Ann Surg Oncol; 2006 Feb; 13(2):198-204. PubMed ID: 16418885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel and accurate computer model of melanoma prognosis for patients staged by sentinel lymph node biopsy: comparison with the American Joint Committee on Cancer model.
    Callender GG; Gershenwald JE; Egger ME; Scoggins CR; Martin RC; Schacherer CW; Edwards MJ; Urist MM; Ross MI; Stromberg AJ; McMasters KM
    J Am Coll Surg; 2012 Apr; 214(4):608-17; discussion 617-9. PubMed ID: 22342785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of autophagy-related proteins expression in resected human gastric adenocarcinoma.
    Qu B; Yao L; Ma HL; Chen HL; Zhang Z; Xie J
    J Huazhong Univ Sci Technolog Med Sci; 2017 Feb; 37(1):37-43. PubMed ID: 28224423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study.
    Thomas NE; Busam KJ; From L; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Venn A; Kanetsky PA; Groben PA; Hao H; Orlow I; Reiner AS; Luo L; Paine S; Ollila DW; Wilcox H; Begg CB; Berwick M
    J Clin Oncol; 2013 Nov; 31(33):4252-9. PubMed ID: 24127443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A population-based validation of the American Joint Committee on Cancer melanoma staging system.
    Gimotty PA; Botbyl J; Soong SJ; Guerry D
    J Clin Oncol; 2005 Nov; 23(31):8065-75. PubMed ID: 16258105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.